Delivery Order SPE2DR25D3002-SPE2DR26FVXW9
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units) with a ceiling value of $1,089.41. This is a firm fixed-price delivery order issued under a non-set-aside competitive procurement process. The order is set to reach completion by November 4, 2025, and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a $30,851.70 delivery order to AmerisourceBergen Drug Corp on December 2, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalation powder (60-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of December 3, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $1,492.84 firm fixed-price delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of Trelegy Ellipta 200-62.5-25 inhalers (60-count units). This is a non-competitive delivery order executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The product will be delivered to AmerisourceBergen's corporate headquarters and...
- The Defense Logistics Agency awarded a delivery order valued at $39,150.40 to AmerisourceBergen Drug Corp on November 18, 2025, for the supply of Trelegy Ellipta 200-62.5-25 inhalers (60-count). This competitively awarded, firm fixed-price contract is set to be completed by November 19, 2025, with performance occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement supporting federal medical...
- The Defense Logistics Agency awarded a $11,097.32 delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for Trelegy Ellipta 100-62.5-25 inhalers (60-count supply). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of October 23, 2025, and performance location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 9, 2025, for the supply of Trelegy Ellipta 200-62.5-25 inhalers (60-count units) with a ceiling value of $5,394.61. This is a firm fixed-price delivery order issued under a non-set-aside competitive procurement, with an ultimate completion date of December 10, 2025. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is a...
- The Defense Logistics Agency awarded a $31,540.49 delivery order to AmerisourceBergen Drug Corp on May 12, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count units). This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of May 13, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a delivery order valued at $5,101.16 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalers (60-count units) on December 1, 2025, with a completion deadline of December 2, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and represents a continuation of the company's pharmaceutical supply services to federal military and healthcare systems. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $7,796.67 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalers (60-count units) on November 24, 2025, with completion targeted for November 25, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Trelegy Ellipta is a combination maintenance inhaler used to treat chronic obstructive pulmonary...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,211.94 to AmerisourceBergen Drug Corp on December 10, 2025, for the supply of Trelegy Ellipta 200-62.5-25 inhalers (60-count units). This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, with an ultimate completion date of December 11, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for...
- SPE2DR25D3002Indefinite Delivery Contract
- SPE2DR25D3002-SPE2DR26FVXW9Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,654.32 to AmerisourceBergen Drug Corp on December 10, 2025, for the supply of Trelegy Ellipta 100-62.5-25 inhalers (60-count package). This is a firm fixed-price, competitively awarded delivery order with an ultimate completion date of December 11, 2025. The contract carries no set-aside designation, and performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal medical supply vendor, AmerisourceBergen leverages this comprehensive IDC to supply a broad portfolio of pharmaceutical products and medical supplies supporting military healthcare systems and other federal customers worldwide. Trelegy Ellipta is a maintenance inhaler used in respiratory disease management, reflecting the company's ongoing role in delivering essential brand-name medications to support the Defense Health Agency and related military healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.7k | 12/9/25 |